Benchmark for tracking industry efforts to fight antimicrobial resistance launched at WEF in Davos

By Gareth Macdonald contact

- Last updated on GMT

Drug industry role in combating antimicrobial resistance discussed at WEF in Davos, Switzerland (Gettyimages/VogelSP)
Drug industry role in combating antimicrobial resistance discussed at WEF in Davos, Switzerland (Gettyimages/VogelSP)

Related tags: Switzerland

The Access to Medicines Foundation has launched a ‘benchmark’ that maps drug industry efforts to stem the spread of drug resistance at the World Economic Forum in Davos, Switzerland.

The Antimicrobial Resistance Benchmark​ – the methodology for which is outlined here​ – was developed as an independent and public tool for measuring how pharmaceutical companies are responding to antimicrobial resistance (AMR).

Drug resistance and antibiotic development have been topics of debate at the WEF for the past few years.

In 2015​, Nobel Prize-winning chemist Venki Ramakrishnan told political and industrial leaders that Governments should do more to support antibiotic development.

He argued that drug industry reliance on profits to fund R&D is a “terrible business model” when it comes to developing antibiotics.

At the event the following year, 85 drug companies and industry associations​ signed a declaration to help combat the spread of antimicrobial resistance.

The agreement called for “Governments to commit funding and support the development and implementation of transformational commercial models that enhance conservation of new and existing antibiotics, while improving financial and access-related predictability for both industry and health systems.​"

The idea was to decouple the R&D investment required for development of antibiotics from revenue generation in order to encourage drug companies to create such products.


The new benchmark will measure what pharmaceutical companies are doing to both develop antibiotics and combat the spread of drug resistance.

According to Access to Medicines, “The first-ever Antimicrobial Resistance Benchmark will map the actions of 30 pharmaceutical companies across three research areas: Research & Development, Manufacturing and Production, Access & Stewardship.

The Benchmark will show where the pharmaceutical industry is taking action, which companies are leading, and where faster progress is needed​.”

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Related suppliers

Follow us


View more